BioLife Solutions, Inc. (BLFS): Price and Financial Metrics
BioLife Solutions, Inc. (BLFS)
Today's Latest Price: $29.24 USD
Updated Oct 29 12:18pm
Add BLFS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BLFS Stock Summary
- BLFS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 573.62 -- higher than 93.82% of US-listed equities with positive expected earnings growth.
- Price to trailing twelve month operating cash flow for BLFS is currently 185.23, higher than 98.02% of US stocks with positive operating cash flow.
- BLFS's price/sales ratio is 25.16; that's higher than the P/S ratio of 93.51% of US stocks.
- Stocks that are quantitatively similar to BLFS, based on their financial statements, market capitalization, and price volatility, are LLNW, XXII, EPAY, PD, and CNTG.
- BLFS's SEC filings can be seen here. And to visit Biolife Solutions Inc's official web site, go to www.biolifesolutions.com.
BLFS Stock Price Chart Interactive Chart >
BLFS Price/Volume Stats
| Current price | $29.24 | 52-week high | $30.31 |
| Prev. close | $29.08 | 52-week low | $7.37 |
| Day low | $28.72 | Volume | 59,575 |
| Day high | $29.81 | Avg. volume | 258,828 |
| 50-day MA | $26.03 | Dividend yield | N/A |
| 200-day MA | $17.71 | Market Cap | 935.74M |
BioLife Solutions, Inc. (BLFS) Company Bio
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company was founded in 1987 and is based in Bothell, Washington.
BLFS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $29.24 | $3.41 | -88% |
We started the process of determining a valid price forecast for Biolife Solutions Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biolife Solutions Inc ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88.17%. As for the metrics that stood out in our discounted cash flow analysis of Biolife Solutions Inc, consider:
- Interest coverage, a measure of earnings relative to interest payments, is -1,238.5; that's higher than just 1.46% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 2.14% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -89% |
| 1% | -88% |
| 2% | -88% |
| 3% | -88% |
| 4% | -88% |
| 5% | -88% |
LGND, RGEN, QGEN, TEVA, and ELAN can be thought of as valuation peers to BLFS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...